Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)
ConclusionsDS showed slightly but nonsignificantly less toxicity and higher efficacy than CS for AGC without measurable lesions. DS should be further investigated in phase III trials.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Anorexia | Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Eating Disorders & Weight Management | Gastric (Stomach) Cancer | Gastroenterology | Hematology | HER2 | Japan Health | Study | Taxotere | Toxicology